icon bookmark-bicon bookmarkicon cameraicon checkicon chevron downicon chevron lefticon chevron righticon chevron upicon closeicon v-compressicon downloadicon editicon v-expandicon fbicon fileicon filtericon flag ruicon full chevron downicon full chevron lefticon full chevron righticon full chevron upicon gpicon insicon mailicon moveicon-musicicon mutedicon nomutedicon okicon v-pauseicon v-playicon searchicon shareicon sign inicon sign upicon stepbackicon stepforicon swipe downicon tagicon tagsicon tgicon trashicon twicon vkicon yticon wticon fm

‘Have you got your Trump yet?’: Geraldo sets liberals off with suggestion Covid-19 vaccine should be named after president

‘Have you got your Trump yet?’: Geraldo sets liberals off with suggestion Covid-19 vaccine should be named after president
Fox News’ Geraldo Rivera has provoked critics of Donald Trump by suggesting the forthcoming Covid-19 vaccine should carry the name of the president, to give him credit.

“I had an idea. With the world so divided and everybody telling him [Trump] he's got to give up and [it's] time to leave and [it's] time to transition and all the rest of it, why not name the vaccine, the Trump?” Rivera suggested on Friday on ‘Fox & Friends’.

Rivera, who counts himself as a friend of the president, said naming the vaccine would be a “nice gesture” for the president to “honor” his work through Operation Warp Speed, a government program meant to accelerate the production and distribution of a Covid-19 vaccine. 

Also on rt.com National Covid-19 shutdown was ‘hypothetical,’ Biden tells reporters, urging nationwide limits on businesses instead

Rivera imagined a world where citizens could refer to the vaccine as “the Trump,” a sound bite that triggered liberal critics on social media.

“Have you got your Trump yet? I got my Trump, I'm fine. You know, I wish we could honor him in that way,” Rivera said.

“@GeraldoRivera may be the the biggest fool in this country not named Trump or Guiliani,” Lincoln Project’s Steve Schmidt tweeted

Pfizer and BioNTech have submitted to the US Food and Drug Administration for emergency use authorization approval of their vaccine candidate, known as BNT162b2, which was found to be 95 percent effective against the virus in clinical trials. The vaccine could be available before the end of the year.

Like this story? Share it with a friend!

Podcasts